Background: Recently, the immunohistochemical detection of estrogen receptor alpha (ERalpha) expression in breast cancer has become a prerequisite for therapeutic decision-making, however, it remains unknown whether ERalpha or progesterone receptor (PgR) expression in histologically normal breast epithelium (NBE) adjacent to carcinoma can be a reliable internal positive control.
Patients And Methods: Tissues from a total of 220 breast cancer patients were investigated by immunohistochemistry of ERalpha and PgR expression in NBE adjacent to carcinoma, as well as in carcinoma. The expression pattern was divided into three groups: singular, one or two positive cells; scattered, scattered positive cells surrounded by negative cells; contiguous, ten or more positive cells in contact with each other.
Results: In NBE adjacent to carcinoma, the positivity of ERalpha and PgR was 99% (217 out of 220) and 89% (195 out of 220), respectively. The expression pattern of ERalpha and PgR was as follows: singular - 13 and 42 patients, scattered - 116 and 100 patients, and contiguous - 88 and 53 patients, respectively. The contiguous expression pattern of PgR was more frequently noted in premenopausal patients in contrast with ERalpha (p=0.0004). PgR expression was more frequently seen in premenopausal than postmenopausal patients (p=0.0034). PgR expression in carcinoma was more frequently seen in premenopausal than postmenopausal patients (p= 0.009). There was statistically significant correlation between PgR expression in carcinoma and NBE adjacent to carcinoma (p=0.0019).
Conclusion: These findings suggest that more frequent PgR expression in NBE adjacent to carcinoma might be correlated with carcinogenesis in premenopausal breast cancer patients and that ERalpha expression, not PgR, in NBE adjacent to carcinoma could be a reliable internal positive control.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Transcription factor FOXD1 and miRNA-204-5p play a major role in B4GALNT2 downregulation in colon cancer.
Sci Rep
January 2025
Department of Medical and Surgical Sciences (DIMEC), General Pathology Building, University of Bologna, Bologna, Italy.
The β1,4-N-acetylgalactosaminyltransferase 2 (B4GALNT2) which synthesizes the histo-blood group antigen Sd is highly expressed by normal colon, but it is dramatically down-regulated in colorectal cancer (CRC). High B4GALNT2 expression in CRC tissues is a marker of longer survival. The molecular bases of B4GALNT2 inhibition in CRC are largely obscure.
View Article and Find Full Text PDFProgesterone receptors regulate susceptibility to spreading depression.
Exp Neurol
January 2025
Department of Neurology, University of Virginia, Charlottesville, VA 22908, USA; Department of Neuroscience, University of Virginia, Charlottesville, VA 22908, USA; UVA Brain Institute, University of Virginia, Charlottesville, VA 22908, USA.
Migraine patients often experience sensory symptoms called auras accompanying the headaches. Cortical spreading depression (CSD), a slow-propagating wave of neuroglial depolarization followed by hyperpolarization is proposed to be the neurological mechanism underlying these auras. We have previously found that progesterone regulates susceptibility to migraine through progesterone receptor (PR) activation.
View Article and Find Full Text PDFWhile most pregnancies are affected by nausea and vomiting, hyperemesis gravidarum (HG) is at the severe end of the clinical spectrum and is associated with dehydration, undernutrition, and adverse maternal, fetal, and child outcomes. Herein we performed a multi-ancestry genome-wide association study (GWAS) of severe nausea and vomiting of pregnancy of 10,974 cases and 461,461 controls across European, Asian, African, and Latino ancestries. We identified ten significantly associated loci, of which six were novel ( , , , , , and and confirmed previous genome-wide significant associations with risk genes , , , and .
View Article and Find Full Text PDFDeeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial.
Nat Commun
January 2025
Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Early therapeutic intervention in high-risk smoldering multiple myeloma (HR-SMM) has shown benefits, however, no studies have assessed whether biochemical progression or response depth predicts long-term outcomes. The single-arm I-PRISM phase II trial (NCT02916771) evaluated ixazomib, lenalidomide, and dexamethasone in 55 patients with HR-SMM. The primary endpoint, median progression-free survival (PFS), was not reached (NR) (95% CI: 57.
View Article and Find Full Text PDFThe guided fire from within: intratumoral administration of mRNA-based vaccines to mobilize memory immunity and direct immune responses against pathogen to target solid tumors.
Cell Discov
January 2025
School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China.
We investigated a novel cancer immunotherapy strategy that effectively suppresses tumor growth in multiple solid tumor models and significantly extends the lifespan of tumor-bearing mice by introducing pathogen antigens into tumors via mRNA-lipid nanoparticles. The pre-existing immunity against the pathogen antigen can significantly enhance the efficacy of this approach. In mice previously immunized with BNT162b2, an mRNA-based COVID-19 vaccine encoding the spike protein of the SARS-CoV-2 virus, intratumoral injections of the same vaccine efficiently tagged the tumor cells with mRNA-expressed spike protein.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!